Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer

BACKGROUND: New therapeutic options for metastatic pancreatic cancer are urgently needed. In pancreatic cancer, overexpression of the epidermal growth factor receptor 2 (HER2) has been reported in up to 45%. This multicentre phase II study investigated the efficacy and toxicity of the HER2 antibody...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Harder, J, Ihorst, G, Heinemann, V, Hofheinz, R, Moehler, M, Buechler, P, Kloeppel, G, Röcken, C, Bitzer, M, Boeck, S, Endlicher, E, Reinacher-Schick, A, Schmoor, C, Geissler, M
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2012
Témata:
Clinical Study
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3304403/
https://ncbi.nlm.nih.gov/pubmed/22374460
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.18
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky